IFNA2 and aggressive systemic mastocytosis: Those with ASM and mast cell leukemia (MCL) may have some benefit from cytoreductive therapies (e.g. interferon alpha-2b or cladribine), although the disease usually recurs and the long-term prognosis is poor.15